中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 35 Issue 4
Apr.  2019
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(4): 830-834

Clinical features of severe acute hypertriglyceridemic pancreatitis

DOI: 10.3969/j.issn.1001-5256.2019.04.024

  • Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University

Research funding:

 

  • Received Date: 2018-10-31
  • Published Date: 2019-04-20
    Abstract
  • Objective To investigate the clinical features of severe acute hypertriglyceridemic pancreatitis ( HTGP) . Methods A retrospective analysis was performed for the clinical data of 179 patients with moderate severe pancreatitis ( MSAP) or severe acute pancreatitis ( SAP) who were admitted to The First Affiliated Hospital of Guangxi Medical University from January 2013 to June 2016. According to the etiology, these patients were divided into severe biliogenic acute pancreatitis ( biliogenic AP) group with 68 patients, severe alcoholic acute pancreatitis ( alcoholic AP) group with 39 patients, severe acute HTGP group with 45 patients, and severe acute pancreatitis group with other causes ( other group) with 27 patients. Related data of the patients with clear causes in the former three groups were recorded, including demographic data, blood triglyceride ( TG) level on the first day of admission, cause, pancreatic necrosis, systemic complications [acute respiratory distress syndrome ( ARDS) , acute renal injury, hypotension, and disseminated intravascular coagulation ( DIC) ], and related clinical outcomes ( admission to the intensive care unit, length of hospital stay, and mortality rate) . In order to investigate the influence of TG concentration on the prognosis of AP patients, the patients were divided into normal blood lipid group with 82 patients, mild dyslipidemia group with 52 patients, moderate dyslipidemia group with 28 patients, and severe dyslipidemia group with 17 patients, according to the TG level on the first day of admission, and the incidence rates of systemic complications, pancreatic necrosis, and clinical outcomes were analyzed. The Kruskal-Wallis H test was used for comparison of continuous data between multiple groups, the chi-square test was used for comparison of categorical data between groups, and the Spearman rank correlation test was used for correlation analysis. Results Biliary tract disease remained the leading cause of SAP ( 38%) , followed by hypertriglyceridemia ( 25%) . As for systemic complications, the HTGP group had a significantly higher incidence rate of ARDS than the biliogenic AP group and the alcoholic AP group ( P = 0. 014 and0. 022) . In the groups with different TG levels, the incidence rates of ARDS and acute renal injury were positively correlated with TG level ( r = 0. 966 and 0. 982, P = 0. 004 and 0. 019) . Conclusion The HTGP group has a higher incidence rate of ARDS than the biliogenic AP group and the alcoholic AP group, and the risk of ARDS and acute renal injury tends to increase with the increasing TG level.

     

    • FullText(HTML)
    • References(31)
  • [1]Pancreas Study Group, Chinese Society of Gastroenterology, Chinese Medical Association, Editorial Board of Chinese Journal of Pancreatology, Editorial Board of Chinese Journal of Digestion. Chinese guidelines for the management of acute pancreatitis (Shanghai, 2013) [J]. J Clin Hepatol, 2013, 29 (9) :656-660. (in Chinese) 中华医学会消化病学分会胰腺疾病学组, 《中华胰腺病杂志》编辑委员会, 《中华消化杂志》编辑委员会.中国急性胰腺炎诊治指南 (2013年, 上海) [J].临床肝胆病杂志, 2013, 29 (9) :656-660.
    [2]NAWAZ H, MOUNZER R, YADAV D, et al. Revised atlanta and determinant-based classification:Application in a prospective cohort of acute pancreatitis patients[J]. Am J Gastroenterol, 2013, 108 (12) :1911-1917.
    [3]XU HF, LI Y, YAN J, et al. Severity analyese of acute pancreatitis based on etiology[J]. Natl Med J China, 2014, 94 (41) :3220-3223. (in Chinese) 徐海峰, 李勇, 颜骏, 等.急性胰腺炎病因与其严重程度的关系[J].中华医学杂志, 2014, 94 (41) :3220-3223.
    [4]HE WH, ZHU Y, ZHU Y, et al. Comparison of severity and clinical outcomes between hypertriglyceridemic pancreatitis and acute pancreatitis due to other causes[J]. Natl Med J China, 2016, 96 (32) :2569-2572. (in Chinese) 何文华, 祝荫, 朱勇, 等.高甘油三酯血症与其他病因所致急性胰腺炎的病情严重程度及预后比较[J].中华医学杂志, 2016, 96 (32) :2569-2572.
    [5]ZHENG YM, ZHOU Z, LI HC, et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years[J]. Pancreas, 2015, 44 (3) :409-414.
    [6]FAN JJ, DING L, LU YY, et al. Epidemiology and etiology of acute pancreatitis in urban and suburban areas in Shanghai:A retrospective study[J]. Gastroenterol Res Pract, 2018, 2018:1420590.
    [7]NESVADERANI M, ESLICK G, VAGG D, et al. Epidemiology, aetiology and outcomes of acute pancreatitis:A retrospective cohort study[J]. Int J Surg, 2015, 23 (Pt A) :68-74..
    [8]WANG Q, WANG G, QIU ZY, et al. Elevated serum triglycerides in the prognostic assessment of acute pancreatitis:A systematic review and Meta-analysis of observational studies[J]. J Clin Gastroenterol, 2017, 51 (7) :586-593.
    [9]BERGLUND L, BRUNZELL JD, GOLDBERG AC, et al. Evaluation and treatment of hypertriglyceridemia:An Endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2012, 97 (9) :2969-2989.
    [10]China Adult Lipid Abnormality Prevention and Treatment Guidelines Revision Committee. Guidelines for the prevention and treatment of adult hyperlipidemia in China (2016 Revision) [J]. Chin Circulation J, 2016, 31 (10) :937-953. (in Chinese) 中国成人血脂异常防治指南修订委员会.中国成人血脂异常防治指南 (2016年修订版) [J].中国循环杂志, 2016, 31 (10) :937-953.
    [11]BURSTOW M, YUNUS R, HOSSAIN M, et al. Meta-analysis of early endoscopic retrograde cholangiopancreatography (ERCP) ±endoscopic sphincterotomy (ES) versus conservative management for gallstone pancreatitis (GSP) [J]. Surg Laparosc Endosc Percutan Tech, 2015, 25 (3) :185-203.
    [12]LLORET L, PELLETIER A, CZERNICHOW S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia[J]. Pancreas, 2008, 37 (1) :13-20.
    [13]GOYAL H, SMITH B, BAYER C, et al. Differences in severity and outcomes between hypertriglyceridemia and alcohol-induced pancreatitis[J]. N Am J Med Sci, 2016, 8 (2) :82-87.
    [14]ZHENG YM, ZHOU X, GAO CC, et al. Risk factors analysis of early death for severe acute pancreatitis patients[J]. China Med Herald, 2017, 14 (13) :61-64. (in Chinese) 郑亚民, 周震, 高崇崇, 等.急性重症胰腺炎早期死亡的风险因素分析[J].中国医药导报, 2017, 14 (13) :61-64.
    [15]CARIOCA A, JOZALA D, BEM L, et al. Severity assessment of acute pancreatitis:Applying Marshall scoring system[J].Rev Col Bras Cir, 2015, 42 (5) :325-327.
    [16]BANKS P, BOLLEN T, DERVENIS C, et al. Classification of acute pancreatitis—2012:Revision of the Atlanta classification and definitions by international consensus[J]. Gut, 2013, 62 (1) :102-111.
    [17]PETROV M, SHANBHAG S, CHAKRABORTY M, et al. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis[J]. Gastroenterology, 2010, 139 (3) :813-820.
    [18]KIM D, CHUNG W, LEE J, et al. Analysis of factors associated with the severity of acute pancreatitis according to etiology[J]. Gastroenterol Res Pract, 2017, 2017:1219464.
    [19]ZENG Y, ZHANG W, LU YY, et al. Impact of hypertriglyceridemia on the outcome of acute biliary pancreatitis[J]. Am J Med Sci, 2014, 348 (5) :399-402.
    [20]WU CY, KE L, TONG ZH, et al. Hypertriglyceridemia is a risk factor for acute kidney injury in the early phase of acute pancreatitis[J]. Pancreas, 2014, 43 (8) :1312-1316.
    [21]LI XY, KE L, DONG J, et al. Significantly different clinical features between hypertriglyceridemia and biliary acute pancreatitis:A retrospective study of 730 patients from a tertiary center[J]. BMC gastroenterology, 2018, 18 (1) :89.
    [22]NAWAZ H, KOUTROUMPAKIS E, EASLER J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis[J]. Am J Gastroenterol, 2015, 110 (10) :1497-1503.
    [23]TSUANG W, NAVANEETHAN U, RUIZ L, et al. Hypertriglyceridemic pancreatitis:Presentation and management[J]. Am J Gastroenterol, 2009, 104 (4) :984-991.
    [24]ALDIVIELSO P, RAMIREZ-BUENO A, EWALD N. Current knowledge of hypertriglyceridemic pancreatitis[J]. Eur J Intern Med, 2014, 25 (8) :689-694.
    [25]CHRISTIAN J, ARONDEKAR B, BUYSMAN E, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dl in patients with severe hypertriglyceridemia[J]. J Clin Lipidol, 2012, 6 (5) :450-461.
    [26]CHAUDHARY A, IQBAL U, ANWAR H, et al. Acute Pancreatitis secondary to severe hypertriglyceridemia:Management of severe hypertriglyceridemia in emergency setting[J]. Gastroenterology Res, 2017, 10 (3) :190-192.
    [27]YANG LL, LI C, WEI XH, et al. Study on the influence of continuous blood purification for serum disease related indexes of patients with severe acute pancreatitis[J]. J Clin Exp Med, 2017, 16 (2) :193-195. (in Chinese) 杨丽丽, 李川, 魏晓华, 等.连续性血液净化对重症急性胰腺炎患者血清疾病相关指标的影响研究[J].临床和实验医学杂志, 2017, 16 (2) :193-195.
    [28]STEFANUTTI C, LABBADIA G, MOROZZI C. Severe hypertriglyceridemia-related acute pancreatitis[J]. Ther Apher Dial, 2013, 17 (2) :130-137.
    [29]SZCZEPIORKOWSKI Z, WINTERS J, BANDARENKO N, et al.Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis[J]. J Clin Apher, 2010, 25 (3) :83-177.
    [30]HUANG SP, TOH DE, SUE Y, et al. Double filtration plasmapheresis in treatment of acute pancreatitis associated with severe hypertriglyceridemia:Three case reports[J]. Medicine, 2018, 97 (44) :e12987.
    [31]KANDEMIR A, COSKUN A, YAVASOGLU I, et al. Therapeutic plasma exchange for hypertriglyceridemia induced acut pancreatitis:the 33 cases experience from a tertiary reference center in Turkey[J]. Turk J Gastroenterol, 2018, 29 (6) :676-683.
    • Relative Articles

  • Relative Articles

    [1]Chunyan ZHAO, Yiqun LI, Li LI. Effect of Bacillus licheniformis preparation on hepatic steatosis and intestinal mucosal barrier function in a rat model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2024, 40(10): 2000-2007. doi: 10.12449/JCH241012
    [2]Yuyan XIA, Qiongrong ZENG, Fujian LI, Fengyan LI, Qi LI, Lixia TANG, Guo ZHANG. Association of intestinal microecology with the development and progression of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(2): 374-379. doi: 10.12449/JCH240225
    [3]Yijie ZHAO, Lu XIE, Yating ZHANG, Guangwei LIU. Pyroptosis： A new bridge connecting gut microbiota and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(9): 1908-1915. doi: 10.12449/JCH240930
    [4]Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
    [5]Qingling ZHONG, Liangping LI. Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(6): 1411-1415. doi: 10.3969/j.issn.1001-5256.2022.06.040
    [6]Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO. Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2676-2679. doi: 10.3969/j.issn.1001-5256.2021.11.041
    [7]Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
    [8]SUN MengYuan, XIANG XiaoXing. Role of gut microbiota and bile acid pathway in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(12): 2831-2834. doi: 10.3969/j.issn.1001-5256.2020.12.040
    [9]Xu Meng, Sun FengXia, Li Jie, Li XiaoLing. Research advances in the role of intestinal flora regulation in the traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1378-1381. doi: 10.3969/j.issn.1001-5256.2020.06.041
    [10]Hui DengCheng, Sun MingYu. Association between nonalcoholic fatty liver disease and gut microbiota based on the theory of gut-liver axis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1627-1630. doi: 10.3969/j.issn.1001-5256.2020.07.039
    [11]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [12]Ceng ShengLan, Lu: Chao, Xiao WeiSong, Tan XiaoBin, Wu Cong, Mao DeWen. Mechanism of action of intestinal flora in hepatic encephalopathy and related treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(10): 2375-2379. doi: 10.3969/j.issn.1001-5256.2020.10.047
    [13]Peng Lu:Cheng, Shao ZhangFeng, Chen JiaQin, Chen Wei. Effect of aerobic exercise combined with silybin on intestinal mucosal barrier in mice with obstructive jaundice[J]. Journal of Clinical Hepatology, 2020, 36(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2020.07.025
    [14]Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
    [15]Wang DanDan, Song Jia, Zhang XiaoLan. Research advances in the role of gut microbiota in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(9): 2120-2123. doi: 10.3969/j.issn.1001-5256.2019.09.053
    [16]Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041
    [17]Pu MinJing, Zhao HongXian, Bo Chao, Zhou XiangYu, Chen Xia. Role and mechanism of the high-mobility group box 1/Toll-like receptor 9 signaling pathway in intestinal mucosal barrier injury in severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1037-1040. doi: 10.3969/j.issn.1001-5256.2019.05.020
    [18]Chen RuiLin, Shen QingYan, Niu KeMin, Yang ZhongTing, Yin XiuWen, Li Xue, Zhou Tao, Chen Jing, Wei BeiHai. Effect of the liver-regulating and spleen-strengthening method on the expression of Toll-like receptor 4 and occludin in the intestinal mucosa of rats with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(10): 2252-2256. doi: 10.3969/j.issn.1001-5256.2019.10.024
    [19]Ding WenJin, Yuan Tao, Shen Feng, Zhou Da, Sun Chao, Fan JianGao, Chen YuanWen. Influence of bisphenol A on intestinal mucosal barrier in rats with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(6): 1268-1272. doi: 10.3969/j.issn.1001-5256.2018.06.027
    [20]Bai ShunYan, Xiao SiJie, Wei Na. Clinical study of changes in intestinal permeability in patients with gallstones of different distribution and properties[J]. Journal of Clinical Hepatology, 2014, 30(6): 546-548. doi: 10.3969/j.issn.1001-5256.2014.06.017
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.6 %FULLTEXT: 4.6 %META: 91.5 %META: 91.5 %PDF: 3.9 %PDF: 3.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.5 %其他: 3.5 %其他: 0.4 %其他: 0.4 %上海: 1.8 %上海: 1.8 %北京: 8.9 %北京: 8.9 %南宁: 0.4 %南宁: 0.4 %南通: 0.7 %南通: 0.7 %吉林: 1.4 %吉林: 1.4 %张家口: 5.3 %张家口: 5.3 %杭州: 0.7 %杭州: 0.7 %深圳: 2.8 %深圳: 2.8 %芒廷维尤: 32.3 %芒廷维尤: 32.3 %芝加哥: 0.4 %芝加哥: 0.4 %莫斯科: 1.1 %莫斯科: 1.1 %西宁: 39.7 %西宁: 39.7 %长春: 0.7 %长春: 0.7 %其他其他上海北京南宁南通吉林张家口杭州深圳芒廷维尤芝加哥莫斯科西宁长春

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1239) PDF downloads(318) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2008]YesterdayPV[3584]TodayIP[1367]TodayPV[2572]Online[94]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return